Can pregnant women use tremelimumab?

Tremelimumab (tremelimumab) exerts its anti-tumor effect by inhibiting the immune checkpoint CTLA-4, releasing the inhibition of T cells, activating the immune system and promoting tumor immune response. However, please note that the specific mechanism of action is still under continuous and in-depth research.

Regarding findings from animal studies and the mechanism of action of temsitumumab, CTLA-4 blockade is associated with a higher incidence of pregnancy loss. In a mouse pregnancy model, CTLA-4 blockade resulted in increased resorption and reduced live fetuses. Mating genetically engineered mice heterozygous for CTLA-4 (CTLA-4+/-) produces CTLA-4+/- offspring and CTLA-4-deficient offspring (homozygous negative, CTLA-4-/-), which are healthy at birth. Fetal damage may occur when temsitumumab is administered to pregnant women. Due to the potential for serious adverse reactions in breastfed children, women are advised not to breastfeed during temsitumumab treatment and for 3 months after the last dose. Women of reproductive potential use effective contraception during temsitumumab treatment and for 3 months after the last dose.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.